Core Viewpoint - 基石药业's stock price increased by over 8% at the close, currently up 6.73% at 6.66 HKD, with a trading volume of 93.12 million HKD, following the approval of a new indication for Shugli monoclonal antibody by the UK MHRA for treating specific adult patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1 - 基石药业 announced that the new indication for Shugli monoclonal antibody has been approved for use in adult patients with advanced NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - 平安证券's research report highlights that 基石药业 is leveraging clinical development as a growth engine, with reliable cash flow from commercialized products in the R&D 1.0 phase and innovative project layouts in the R&D 2.0 phase [1] - The core products of 基石药业 have entered clinical trial stages, with plans to continue advancing candidate projects into clinical trials, projecting revenues of 195 million, 464 million, and 633 million CNY for the years 2025, 2026, and 2027 respectively [1]

消息面上，基石药业此前宣布，舒格利单抗的新适应症申请已获英国MHRA批准单药用于治疗肿瘤细胞 PD-L1表达≥1%、无表皮生长因子受体（EGFR）敏感突变或ALK、ROS1基因组变异、在含铂放化疗 （CRT）后未出现疾病进展的、不可切除的III期NSCLC成人患者。 平安证券发布研报称，基石药业以临床开发为引擎，研发1.0阶段商业化产品贡献可靠现金流量，研发 2.0阶段项目创新布局研发管线及前沿技术，核心品种已迈入临床试验阶段且后续将持续推进候选项目 进入临床，预计2025-2027年公司实现收入1.95/4.64/6.33亿元，首次覆盖给予"推荐"评级。 智通财经APP获悉，基石药业-B(02616)尾盘涨超8%，截至发稿，涨6.73%，报6.66港元，成交额9312.3 万港元。 ...

消息面上，2月23日，基石药业宣布，其PD-L1抗体舒格利单抗针对III期非小细胞肺癌(NSCLC)的新适 应症，已正式取得英国药品和医疗保健用品管理局(MHRA)的批准。此次获批是该适应症继2024年7月 获得欧盟委员会(EC)许可之后，在欧洲核心市场取得的又一关键突破。 此外，基石药业核心资产CS2009用于晚期实体瘤的II期临床试验IND申请近期获得FDA批准。 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验申请(IND)获美国食品药 品监督管理局(FDA)批准，标志着这一创新免疫疗法的全球开发取得重要进展。 基石药业-B(02616)再涨超6%，月内累计涨幅已超25%。截至发稿，涨5.03%，报6.68港元，成交额1.02 亿港元。 ...

此外，基石药业核心资产CS2009用于晚期实体瘤的II期临床试验IND申请近期获得FDA批准。 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验申请(IND)获美国食品药 品监督管理局(FDA)批准，标志着这一创新免疫疗法的全球开发取得重要进展。 消息面上，2月23日，基石药业宣布，其PD-L1抗体舒格利单抗针对III期非小细胞肺癌(NSCLC)的新适 应症，已正式取得英国药品和医疗保健用品管理局(MHRA)的批准。此次获批是该适应症继2024年7月 获得欧盟委员会(EC)许可之后，在欧洲核心市场取得的又一关键突破。 智通财经APP获悉，基石药业-B(02616)再涨超6%，月内累计涨幅已超25%。截至发稿，涨5.03%，报 6.68港元，成交额1.02亿港元。 ...

来源：智通财经网 基石药业-B(02616)涨超5%，截至发稿，涨5.12%，报6.36港元，成交额2393.21万港元。 继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获英国MHRA批准，这是该产品在英国 获得的第二个适应症批准。据悉，舒格利单抗已在欧洲、中东及非洲、拉丁美洲达成四项商业化合作， 累计覆盖六十余个国家和地区，海外的商业化工作正在积极开展中。 消息面上，基石药业昨日公布，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局 (MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、 ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人 患者。 ...

智通财经APP获悉，基石药业-B(02616)涨超5%，截至发稿，涨5.12%，报6.36港元，成交额2393.21万港 元。 消息面上，基石药业昨日公布，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局 (MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、 ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人 患者。 继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获英国MHRA批准，这是该产品在英国 获得的第二个适应症批准。据悉，舒格利单抗已在欧洲、中东及非洲、拉丁美洲达成四项商业化合作， 累计覆盖六十余个国家和地区，海外的商业化工作正在积极开展中。 ...

Important Events - BGI Genomics plans to sell 100% equity of Complete Genomics for $50 million and adjust the licensing of CoolMPS sequencing technology [1] - Base Pharmaceuticals received approval from the UK MHRA for Sugli monoclonal antibody's new indication in non-small cell lung cancer [1] - Frontline Bio signed a licensing agreement with GlaxoSmithKline, receiving an upfront payment of $40 million and potential milestone payments totaling up to $950 million (approximately 6.56 billion RMB) [1] - Bai Li Tian Heng's clinical trial for iza-bren (EGFR×HER3 dual antibody ADC) in locally advanced or metastatic triple-negative breast cancer reached its primary endpoint in interim analysis [1] - Huagong Technology's AI high-speed optical module orders are scheduled to run through the fourth quarter, with production bases in Wuhan and Thailand fully operational [1] - Wuliangye has distributed over 76.8 billion RMB in dividends over the past five years [1] - Tongfu Microelectronics' application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [1] Bids - Donghong Co., Ltd. won a procurement project for pressure steel pipes and accessories worth 353 million RMB [1] - Jintanglan's subsidiary won a project for the Sabah Intercontinental Resort Hotel in Malaysia, amounting to approximately 281 million RMB [1] - Shuangliang Energy's wholly-owned subsidiary won a bid for the cooling island system of an H-class combined cycle power plant project in the Middle East, with a bid amount of 100.26 million RMB [1] Performance - Jiantao Group expects a more than 165% increase in net profit for 2025 compared to the same period in 2024 [1] Buybacks & Increases - Luxshare Precision conducted its first share buyback, repurchasing 9.9 million shares for nearly 500 million RMB [2] - Tongce Medical's chairman and others plan to increase their holdings in the company by 6 to 12 million RMB [2]

Group 1 - Heptares Therapeutics has entered into a licensing and equity cooperation agreement with Solstice Oncology for HBM4003, granting exclusive rights for development and commercialization outside Greater China, with potential upfront payments exceeding $105 million [1] - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, one of which is in the IND stage, marking a significant breakthrough in its international strategy [2] - CStone Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new indication of Sugli monoclonal antibody for treating adult patients with advanced non-small cell lung cancer, highlighting its global operational capabilities [3] Group 2 - Novo Nordisk's stock has dropped significantly following the disappointing clinical data for CagriSema, which showed only a 23% weight loss effect, failing to meet the primary endpoint of the trial [4] - Tongce Medical's chairman and executives have announced plans to increase their shareholding in the company, aiming to stabilize market sentiment amid pressures from weak consumer demand and dental implant procurement [5]

丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协 议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶 段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价。 2月23日，基石药业公告称，舒格利单抗的新适应证申请已获英国药品和医疗保健用品管理局批准单药 用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂 放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。 点评：这是舒格利单抗出海进程的又一里程碑。不过，非小细胞肺癌领域PD-1/PD-L1竞争白热化，基 石药业需依托合作伙伴的本地化商业化能力抢占份额，本次获批更多体现监管认可度与全球化运营能力 的提升。 NO.4 诺和诺德股价大跌，CagriSema临床数据不及预期 2月23日，丹麦药企诺和诺德股价大跌。消息面上，公司公布了CagriSema临床 ...

Company News - Tongguan Gold (00340.HK) expects a net profit of approximately HKD 820 million to HKD 840 million in 2025, representing a year-on-year increase of about 289% to 298%, mainly due to increased production and sales of gold and higher average selling prices [1] - China State Construction Industry (00830.HK) anticipates a net profit of approximately HKD 237 million for the fiscal year 2025, down from HKD 650 million in the previous year, primarily due to a decrease in new project volume and revenue [1] - Kintor Group (00148.HK) projects a net profit growth of over 165% in 2025, exceeding HKD 4.32 billion, driven by growth in investment business and profits from copper-clad laminates [1] - Kintor Laminates (01888.HK) expects a net profit increase of over 80% in 2025, exceeding HKD 2.39 billion, attributed to strong demand for copper-clad laminates and upstream materials including fiberglass yarn, fiberglass cloth, and copper foil [1] - China Starch (03838.HK) forecasts total revenue of RMB 10.058 billion in 2025, with a pre-tax profit of RMB 838 million, a significant decrease of approximately 64% year-on-year [2] Other Developments - Wuyi Vision (06651.HK) has successfully completed systematic adaptation and deep optimization of SimOne 4.0 on the Moore Thread MTT S5000 GPU [3] - China Resources Land (03377.HK) issued a total of 1,996,400 new shares due to the conversion of mandatory convertible bonds [3] - Cornerstone Pharmaceuticals-B (02616.HK) received approval from the UK MHRA for a new indication of Sugliucan in the treatment of small cell lung cancer [4] - MIRXES-B (02629.HK) completed the enrollment process for the CADENCE CRC study [5] - Jingrui Holdings (01862.HK) received additional resumption guidance from the Stock Exchange and continues to be suspended [6] Buyback Activities - Xuanwu Cloud (02392.HK) repurchased 4,000 shares at a cost of HKD 6.22778 million, with buyback prices ranging from HKD 1.52 to HKD 1.57 [7] - Geely Automobile (00175.HK) spent HKD 11.263 million to repurchase 659,000 shares, with buyback prices between HKD 16.99 and HKD 17.18 [8] - NetEase Cloud Music (09899.HK) repurchased approximately HKD 14.9977 million worth of 94,500 shares, with buyback prices ranging from HKD 157.2 to HKD 160.9 [9]